Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes

Circulation Research

Volumn 86, Issue 2, 2000, Pages 158-165

  Gilbert, Richard E ^a,b   Rumble, Jonathan R ^a   Cao, Zemin ^a   Cox, Alison J ^a   Van Eeden, Pauline ^a   Allen, Terri J ^a   Kelly, Darren J ^a   Cooper, Mark E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Diabetes; Endothelin; Growth factor; Mast cell; Vasculature

Indexed keywords

BOSENTAN; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; EPIDERMAL GROWTH FACTOR; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL DIAMETER; CELL INFILTRATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG EFFECT; EXTRACELLULAR MATRIX; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT;

EID: 0033964675     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.86.2.158     Document Type: Article

References (13)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035-2038.
2. Clark CJ, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 1995;332:1210-1217.
3. Griffin SA, Brown WC, MacPherson F, McGrath JC, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991;17:626-635.
4. Simonsen U, Ehrnrooth E, Gerdes LU, Faergemann O, Buch J, Andreasen F, Mulvany MJ. Functional properties in vitro of systemic small arteries from rabbits fed a cholesterol-rich diet for 12 weeks. Clin Sci. 1991;80: 119-129.
5. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerums G, Gilbert RE. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest. 1997;99: 1016-1027.
6. Palmer AM, Gopaul N, Dhir S, Thomas CR, Poston L, Tribe RM. Endothelial dysfunction in streptozotocin-diabetic rats is not reversed by dietary probucol or simvastatin supplementation. Diabetologia. 1998;41: 157-164.
7. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994;43:1221-1228.
8. Bray P, Agrotis A, Bobik A. Transforming growth factor-beta and receptor tyrosine kinase-activating growth factors negatively regulate collagen genes in smooth muscle of hypertensive rats. Hypertension. 1998;31:986-994.
9. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996;45:522-530.
10. Gilbert RE, Cox A, McNally PG, Dziadek M, Wu LL, Cooper ME, Jerums G. Increased epidermal growth factor expression in diabetes related kidney growth. Diabetologia. 1997;40:778-785.
11. Furcht LT. Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors. Lab Invest. 1986;55:505-509.
12. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL. Human mast cells stimulate vascular tube formation: tryptase is a novel, potent angiogenic factor. J Clin Invest. 1997;99:2691-2700.
13. Laine P, Kaartinen M, Penttilä A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation. 1999;99: 361-369.